HomeAgenda
Register
Register
Register

Project cooperationUpdated on 28 August 2025

SSD-004 for Systemic Scleroderma (SSc)

About

SSD-004 (API: 2ccPA) abrogates ECM production and promotes antifibrotic molecules from SSc skin fibroblasts. SSD-004 also at tenuates the progression of fibrosis in bleomycin-induced skin fibrosis. These findings suggest that SSD-004 may be a promising antifibrotic agent for the treatment of SSc.

Stage

  • Execution

Type

  • Research
  • Technical
  • Sales/Distribution
  • Financing

Organisation

SANSHO Co., Ltd.

Company (SME/startup) / 中小企業・スタートアップ

Tokyo, Japan

Similar opportunities